Cullinan Therapeutics (CGEM) Research & Development (2020 - 2026)

Cullinan Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $42.1 million for Q1 2026.

• In Q1 2026, Research & Development rose 1.6% year-over-year to $42.1 million; the TTM figure through Mar 2026 stood at $188.1 million (up 22.35% YoY), while the FY2025 annual figure was $187.4 million, up 31.14% from the prior year.
• Research & Development for Q1 2026 stood at $42.1 million, down from $42.9 million in the prior quarter.
• The five-year high for Research & Development was $61.0 million in Q2 2025, with the low at $19.7 million in Q3 2022.
• The 5-year median for Research & Development is $35.5 million (2024), against an average of $36.0 million.
• The sharpest annual moves came in 2022 and 2024: Research & Development soared 124.24% in 2022, then sank 41.17% in 2024.
• Cullinan Therapeutics' Research & Development stood at $21.3 million in 2022, then jumped by 63.44% to $34.8 million in 2023, then climbed by 16.2% to $40.5 million in 2024, then rose by 6.06% to $42.9 million in 2025, then retreated by 1.91% to $42.1 million in 2026.
• Business Quant data shows CGEM's Research & Development at $42.1 million in Q1 2026, $42.9 million in Q4 2025, and $42.0 million in Q3 2025.